# Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

> **NCT07146113** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 400 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07146113
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146113, "Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07146113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*